Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting
Links shared publicly online about this topic.
- 1,548total visits
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
View full resource at news-medical.net
Tags: Leukemia, Acute Myelogenous Leukemia, Pharma, Clinical Trial
Most Recently Shared on December 7, 2009 at 2:26 pm By:
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting: Celator Pharmaceuticals toda... http://bit.ly/6ThC4N
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American Society Of Hematology Meeting
medicalnewstoday.com — “Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection” View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2009 at 5:36 pm By:
MNT Clinical Trials Health News
Celator(R) Pharmaceuticals Presents Interim Data From Phase 2 Study Of CPX-351 In Newly Diagnosed AML At American S... http://bit.ly/5umdYQ
Advertisement
